June 5, 2020
Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab) was the best-selling drug in Japan in May, outstripping MSD rival Keytruda (pembrolizumab) to snap its one-year winning streak, according to a monthly snapshot report released by market research firm Encise. Opdivo pulled in...read more